Skip to content

Eskanbil in male idiopathic infertility

Evaluation of the effects of Calligonum comosum (Eskanbil) extract on semen parameters of men with idiopathic oligoasthenoteratozoospermia.

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20150420021869N11
Enrollment
40
Registered
2026-04-25
Start date
2026-05-22
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Male infertility. Male infertility

Interventions

Intervention group: all patients are treated with 500 mg of Eskanbil extract in the form of oral capsule for three months..

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Men aged 20 to 45 years Idiopathic infertility Sperm count less than 16 million per milliliter Total motility less than 42% or progressive motility less than 30% Normal sperm morphology less than 4%

Exclusion criteria

Exclusion criteria: Pyospermia History of testicular surgery History of chemotherapy or radiotherapy Cigarette smoking History or current use of medications affecting spermatogenesis, such as tamoxifen, hCG, cytotoxic drugs (e.g., immunosuppressants, anticonvulsants, androgens) History of sexually transmitted infections (STIs) History of epididymo-orchitis History of testicular trauma History of prostatitis Lack of willingness to participate in the study Chromosomal abnormalities History of testicular torsion

Design outcomes

Primary

MeasureTime frame
Semen volume. Timepoint: At baseline and 3 months after the intervention. Method of measurement: Semen analysis.;Sperm DNA fragmentation index. Timepoint: At baseline and 3 months after the intervention. Method of measurement: Tunnel test.;Sperm concentration. Timepoint: At baseline and 3 months after the intervention. Method of measurement: Semen analysis.;Sperm motility. Timepoint: At baseline and 3 months after the intervention. Method of measurement: Semen analysis.;Sperm morphology. Timepoint: At baseline and 3 months after the intervention. Method of measurement: Semen analysis.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarshad Gholipour

Esfahan University of Medical Sciences

farshad.gholipoor@gmail.com+98 31 3669 7898

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026